Echocardiographic Assessment of Residual Mitral Regurgitation to Predict Outcomes Following Mitral Trans-Catheter Edge-to-Edge Repair: Intra-Procedure TEE Versus Post-Procedure TTE

Document Type

Conference Proceeding

Publication Date

6-2026

Publication Title

Structural Heart

Abstract

Background: The relative ability of intra-procedural TEE versus post-procedure TTE to predict clinical outcome after mitral TEER has not been established. Methods: We performed a retrospective cohort study of patients undergoing mitral TEER utilizing data from the Michigan Structural Heart Consortium (MISHC), a statewide multicenter collaborative registry. A McNemar test was performed to assess agreement in MR grade between the two echo modalities. Numeric variables were summarized by means and standard deviations; categorical variables were summarized by counts and frequencies. Unadjusted differences across levels of MR were tested with one-way ANOVA (numeric) and chi-square or Fisher exact tests (categorical). Results: The study cohort comprised 2310 patients treated between January 1, 2016, to December 21, 2024. Patients were majority male (54.6%) with a median age of 77.4 years, and 80.5% of patients were in New York Heart Association (NYHA) class III/IV. At baseline, 87.3% patients had ≥moderate-severe MR. By intraprocedural TEE, 395 (17.1%) had trace MR, 1351 (58.5%) had mild MR and 564 (24.4%) had ≥ moderate MR post TEER. By postprocedural TTE, 474 (20.5%) had trace MR, 1302 (56.4%) had mild MR and 534 (23.2%) had ≥ moderate MR post TEER. There was discordance in MR grading in 893 (38.7%) of patients (p=0.003). Effect of MR grade on various adverse outcomes, as assessed by either intraprocedural TEE or post-procedural TTE, is summarized in the table. Conclusion: Despite discordance in grading of residual MR following mitral TEER as assessed by intraprocedural TEE versus post-procedural TTE, the presence of residual ≥ moderate MR as assessed by either modality predicted increased mortality at 1 year, increased NYHA class at 30 days and 1 year, increased heart failure readmissions at 30 days and 1 year, and decrease in KCCQ score at 30 days and 1 year.

Volume

10

Issue

6 Suppl

First Page

100940

Comments

New York Valves The Structural Heart Summit, June 24-26, 2026, New York, NY

Last Page

100940

DOI

10.1016/j.shj.2026.100940

Share

COinS